Corbus Pharmaceuticals Holdings, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this filing is an annual Form 10-K and reports full-year results. Filed March 12, 2024.
Business context
Corbus is a clinical-stage precision oncology and obesity biotechnology company with no approved products and no product revenue. Its pipeline includes CRB-701, a Nectin-4 antibody-drug conjugate for solid tumors; CRB-601, an anti-integrin αvβ8 antibody intended to inhibit TGFβ activation in solid tumors; and CRB-913, a peripherally restricted CB1 inverse agonist for obesity.
- CRB-701: Licensed from CSPC in February 2023 for specified territories. CSPC was conducting a Phase 1 dose-escalation trial in China. Data through December 2023 from 18 patients showed a 43% overall response rate and 71% disease control rate among seven patients receiving predicted therapeutically relevant doses. The company planned to begin a U.S. Phase 1 trial in the first quarter of 2024.
- CRB-601: FDA cleared the IND in January 2024; the company expected to enroll the first patient in a Phase 1 trial in summer 2024.
- CRB-913: In IND-enabling studies, with an IND filing targeted for the fourth quarter of 2024. Positive findings cited are limited to preclinical mouse models.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue from products, awards and licenses | $0 | $0 | No change |
| Research and development expense | $31.2 million | $16.1 million | +$15.0 million |
| General and administrative expense | $13.9 million | $18.7 million | -$4.8 million |
| Litigation settlement expense | $0 | $5.0 million | -$5.0 million |
| Total operating expenses | $45.1 million | $39.8 million | +$5.2 million |
| Net loss | $44.6 million | $42.3 million | Loss increased $2.3 million |
| Net loss per share | $10.31 | $10.15 | Loss per share increased |
| Net cash used in operating activities | $36.1 million | $37.5 million | Use decreased $1.4 million |
Operating expenses represented substantially all activity because Corbus has no commercial products. The filing does not provide a meaningful revenue-based margin; the company remains loss-making and had an accumulated deficit of approximately $436.7 million at December 31, 2023.
- Cash and cash equivalents were $13.7 million, investments were $7.2 million, and total cash, cash equivalents and restricted cash were $14.4 million at year-end. Cash, cash equivalents and investments totaled approximately $20.9 million.
- Total assets were $28.3 million, current liabilities were $31.9 million, and stockholders’ equity was negative $6.9 million, resulting in negative working capital of approximately $8.3 million.
- Debt included approximately $15.9 million of current long-term debt under the K2 HealthVentures loan, with a stated maturity of August 1, 2024. The loan carried an interest rate of 13.75% at year-end, was secured by substantially all company assets, and was subject to financial and operational covenants.
- Operating cash use was partially offset by $35.6 million of investment proceeds, while financing activities used $2.8 million, primarily for debt repayment.
- Research and development expense included a $7.5 million CRB-701 upfront license payment and $2.325 million of UCSF development milestones.
Material changes versus 2022
- R&D expense nearly doubled, primarily because of the CSPC license payment, UCSF milestones, higher CRB-601 manufacturing costs, increased preclinical and clinical preparation costs, and higher regulatory, quality and manufacturing support costs.
- G&A expense declined due to lower stock-based compensation, lower legal costs related to the Venn Therapeutics litigation, lower insurance premiums and reduced consulting costs.
- The $5.0 million Venn litigation settlement recorded in 2022 did not recur.
- Other income improved to $474,000 from a $2.5 million expense in 2022, primarily because of approximately $2.6 million of refundable foreign research and development credits related to the prior year.
- Common shares outstanding increased to 4.42 million at December 31, 2023 from 4.17 million, including shares issued through the ATM program, stock-option exercises and conversion of $875,000 of K2 debt.
- Corbus completed a 1-for-30 reverse stock split on February 14, 2023. Historical per-share information in the filing has been adjusted retroactively.
Guidance, outlook, risks and unusual items
- Management expects 2024 R&D expense to decline because the CRB-701 upfront payment will not recur and substantial CRB-601 manufacturing costs were incurred in 2023. Losses and operating cash use are nevertheless expected to continue for several years.
- Following year-end, Corbus completed a February 2024 public offering of 4.974 million shares, including the fully exercised over-allotment, for approximately $94.5 million of gross proceeds and $88.5 million of net proceeds. Together with approximately $21.2 million of aggregate ATM proceeds through the filing date, management estimated funding through the first quarter of 2027 based on current planned expenditures.
- The company terminated the current ATM prospectus supplement in January 2024 and stated that no further ATM sales would occur unless a new shelf registration statement and prospectus supplement were filed.
- Nasdaq had notified Corbus in November 2023 that it did not meet the $2.5 million minimum stockholders’ equity requirement. Nasdaq later confirmed in February 2024 that the company regained compliance under the alternative market-value standard. Continued compliance is not assured.
- Corbus remains dependent on additional financing. Failure to raise capital could require delaying, scaling back or discontinuing clinical and preclinical programs. Equity financing may dilute existing stockholders.
- Key operating risks include clinical-trial failure or delay, regulatory rejection, manufacturing dependence, reliance on CSPC and other third parties, U.S.-China trade and geopolitical risks, intellectual-property challenges, competition, reimbursement uncertainty and potential adverse drug effects.
- Potential future license obligations are substantial: CSPC milestone payments of up to $130 million in development and regulatory milestones plus $555 million in commercial milestones; UCSF milestones of up to $153.15 million, excluding certain indication milestones; and additional obligations under the Jenrin license. Royalties would also apply to future sales.
- The company relies on third-party manufacturers and does not own manufacturing facilities. The CSPC supply arrangement for CRB-701 is particularly important to clinical development and any future commercialization.
- Management reported that a material weakness identified in 2023 involving accruals for upfront license payments and issue fees was remediated as of December 31, 2023. Management concluded that disclosure controls and internal control over financial reporting were effective at year-end; the external auditor was not required to provide an internal-control attestation.
- The company is in the process of terminating its facility sublease and does not expect additional sublease income beyond the first quarter of 2024. The primary lease runs through November 2026.
Important facts for investors to verify
- Reconcile the reported year-end liquidity with the subsequent February 2024 equity offering and the estimated runway through the first quarter of 2027.
- Track the K2 loan maturity, required repayments, covenant compliance and the March 2024 conversion of an additional $1.125 million into 142,857 shares.
- Verify the timing, enrollment and safety and efficacy data from the CRB-701 U.S. Phase 1 trial and the planned CRB-601 Phase 1 trial.
- Assess whether CRB-701 data generated in China will be accepted by U.S. regulators and whether additional U.S.-based studies will be required.
- Review dilution from the February 2024 offering, ATM issuance, outstanding options, warrants, restricted stock units and the annual equity-plan share increase.
- Monitor Nasdaq continued-listing compliance and the company’s future financing needs.
- Review the CSPC license terms, manufacturing and supply arrangements, milestone obligations and royalty rates before assigning commercial value to CRB-701.
- Confirm the status of the remediated internal-control weakness and the accuracy of accrued clinical and preclinical expenses, which totaled approximately $7.0 million in the year-end audit discussion.